Niagen Plus: Why the NAD+ Market Just Went Injectable
BiohackingThe NAD+ supplement category spent its first decade proving that oral nicotinamide riboside (NR) could reliably raise blood NAD+ levels. It succeeded. Niagen Bioscience reported $129.4 million in 2025 revenue — up 30% year over year. The market has now moved to the next question: what happens when you bypass the gut entirely?
Niagen Bioscience’s newly launched Niagen Plus telehealth platform answers that with a prescription-only, clinician-directed at-home injection kit — the first commercially available subcutaneous NR product sold direct to eligible US patients via telehealth.
Context
Oral NR has a well-documented bioavailability ceiling. The compound is absorbed through the gut, converted to NAD+ through a multi-step metabolic pathway, and distributed to tissues. Subcutaneous injection bypasses that first-pass metabolism, delivering the compound more directly into systemic circulation. Whether this translates into meaningfully higher tissue-level NAD+ concentrations in humans — and whether that elevation produces functional health benefits — remains an active area of research. The mechanism is plausible; the clinical significance for healthy adults is still being established.
What changed with the Niagen Plus launch is not the science — it’s the delivery infrastructure. Telehealth platforms have made prescription access to compounds like semaglutide and testosterone dramatically more accessible. The same model is now being applied to longevity biochemistry.
The Detail
The Niagen Plus kit is dispensed by a licensed 503A compounding pharmacy after a clinician-directed telehealth intake process. Eligible US patients complete an online medical form, consult with a licensed provider, and — if prescribed — receive a kit shipped to their door for $299.
The kit contains a sterile 500 mg vial of pharmaceutical-grade Niagen (nicotinamide riboside chloride, NRCl) powder, bacteriostatic water for reconstitution, mixing syringes, injection syringes, alcohol prep pads, and step-by-step instructions accessible via QR code. Clinicians determine dosing at either 50 mg or 100 mg per injection based on individual assessment.
The company’s internal safety trial showed the injectable formulation was “generally well tolerated at these doses, with no significant adverse effects reported,” per CEO Rob Fried. The platform is not currently available to patients in Alabama or California.
The launch positions Niagen Plus alongside an emerging class of longevity-focused telehealth platforms — including peptide therapy providers and GLP-1 adjacent services — that use compounding pharmacies to bridge the gap between research-stage compounds and consumer access.
The So What
For the self-directed biohacker, the Niagen Plus launch is a signal worth tracking, not a protocol to adopt immediately. Injectable NAD+ precursor delivery is a meaningful formulation advance on paper, but the independent clinical evidence for injectable NR specifically — as distinct from IV NAD+ infusions, which have their own limited evidence base — is thin. The telehealth model adds appropriate clinical guardrails, which matters for a compound whose long-term effects in healthy adults are still being characterized.
The structural shift is more significant than any single product: the longevity supplement market is industrializing its delivery mechanisms. As reviewed in NR Sales Hit $129M: What Niagen Bioscience’s 30% Growth Signals About the NAD+ Market, the NR category is already moving from niche to mainstream. Injectable access via telehealth is the next step in that maturation — bringing higher-precision delivery to the portion of the market willing to pay for it. Consult a qualified healthcare provider before pursuing any injectable supplement protocol.
Photo by Gustavo Fring on Pexels
Source: Longevity.Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →